Despite being unable to declare statistical success, the company claimed its therapy showed enough promise to support moving ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

The gene therapy developer has lost most of its value since going public in 2020 and saw a long road ahead for a delivery ...

The approval could help Enhertu, which is already a multibillion-dollar seller, supplant a regimen that’s been the standard ...